Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, double-blind, placebo-controlled, crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 antagonist + dexamethasone in patients with germ cell tumors undergoing 5 day cisplatin-based chemotherapy regimen.

Next Previous
X
Search
Trial Profile

Phase III, double-blind, placebo-controlled, crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 antagonist + dexamethasone in patients with germ cell tumors undergoing 5 day cisplatin-based chemotherapy regimen.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone; Serotonin 3 receptor antagonists
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 20 Aug 2012 Results published in the Journal of Clinical Oncology.
    • 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 16 Feb 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top